Clinical Trial Update: Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 trial results for TC-5619 in adults with inattentive-predominant ADHD report safety and efficacy data. The study was conducted by Targacept Inc. and is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• TC-5619

Snippet

Sponsor: Targacept Inc. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED